Belz              G.G. Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology // Br. J. Clin. Pharmacol. - 2003. -
N. 56. - P. 3-10.
Benjamin              N., Vallance P. Local control of human peripheral vascular tone: implications for drug therapy // Clin. Sci. - 1991. - N. 80. - P. 183-190.
Kam              P.C., Williams S., Yoong F.F. Vasopressin and terlipressin: pharmacology and its clinical relevance // Anaesthesia. - 2004. - N. 59. - P. 993-1001.
4.Sastry B.K., Narasimhan C., Reddy N.K. et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study // J. Am. Coll. Cardiol. - 2004. - N. 43. - P. 1149-1153.
Law              M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis // BMJ. - 2003. - N. 326. - 1423 p.
Edwards              I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management // Lancet. -
- N. 356. - P. 1255-1259.
7.SoRelle R. Baycol withdrawn from market // Circulation. - 2001. - N. 104. - P. 9015-9016.
Abourjaily              H.M., Alsheikh-Ali A.A., Karas R.H. Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin // Am J Cardiol. - 2003. - N. 91. - P. 999-1002, 1007.
Parish              R.C., Miller L.J. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update // Drug Saf. - 1992. - N. 7. - P. 14-31.
10.Shah S.U., Anjum S., Littler W.A. Use of diuretics in cardiovascular disease: (2) hypertension // Postgrad. Med. J. - 2004. - N. 80. - P. 271-276.
.Zannad F., Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies // Fundam. Clin. Pharmacol. - 2007. - N. 21. - P. 181-190.
Wetzels              G.E., Nelemans P., Schouten J.S. et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review // J. Hypertens. - 2004. - N. 22. - P. 1849-1855.
Kirchheiner              J., Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms // Clin. Pharmacol. Ther. - 2005. - N. 77. - P. 1-16.
Bailey              D.G., Dresser G.K. Interactions between grapefruit juice and cardiovascular drugs // Am. J. Cardiovasc. Drugs. - 2004. - N. 4. - P. 281-297.
Hall              A.M., Wilkins M.R. Warfarin: a case history in pharmacogenetics // Heart. - 2005. - N. 91. - P. 563564.
Pedersen              A.K., FitzGerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase // N. Engl. J. Med. - 1984. - N. 311. - P. 1206-1211.
Williams              B., Poulter N.R., Brown M.J. et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary // BMJ. - 2004. - N. 328. - P. 634-640.
Pirmohamed              M., Park B.K. Genetic susceptibility to adverse drug reactions // Trends Pharmacol. Sci. -
- N. 22. - P. 298-305.
19.Staessen J.A., Wang J.G., Birkenhager W.H. Outcome beyond blood pressure control? // Eur. Heart J. - 2003. - N. 24. - P. 504-514.
20.Halcox J.P., Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy // Circulation. - 2004. - N. 109. - 1142-1148.
21 .Safety concerns at the FDA // Lancet. - 2005. - N. 365. - P. 727-728.
European              Medicines Agency. The clinical evaluation of QT/Q-Tc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14. Available at http://www.emea.eu.int
The              European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products. Points to consider: the assessment of the potential for QT interval prolongation by noncardiovascular medicinal. products. Available at http://www.emea.eu.int
Finlayson              K., Witchel H.J., McCulloch J. et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development // Eur. J. Pharmacol. - 2004. - N. 500. - P. 129-142.
Borer              J.S., Pouleur H., Abadie E. et al. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval // Eur. Heart J. - 2007. - N. 28. -
P. 1904-1909.
Wu              A.H. Cardiotoxic drugs: clinical monitoring and decision making // Heart. - 2008. - N. 94. - P. 15031509.
Roden              D.M., Altman R.B., Benowitz N.L. et al. Pharmacogenomics: challenges and opportunities // Ann. Intern. Med. - 2006. - N. 145. - P. 749-757.
Guidance              for Industry Pharmacogenomic Data Submissions. U.S. Food and Drug Administration (March 2005). http://www.fda.gov.
Wadelius              M., Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges // Pharmacogenomics J. - 2007. - N. 7. - P. 99-111.
Faraday              N., Becker D.M., Becker L.C. Pharmacogenomics of platelet responsiveness to aspirin // Pharmacogenomics. - 2007. - N. 8. - P. 1413-1425.
Beitelshees              A.L., McLeod H.L. Clopidogrel pharmacogenetics: promising steps towards patient care?
// Arterioscler. Thromb. Vasc. Biol. - 2006. - N. 26. - P. 1681-1683.
Brodde              O.E. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses // Pharmacol. Ther. - 2008. - N. 117. - P. 1-29.
Azuma              J., Nonen S. Chronic heart failure: beta-blockers and pharmacogenetics // Eur. J. Clin. Pharmacol. - 2009. - N. 65. - P. 3-17.
Brugts              J.J., Danser A.H., de Maat M.P. et al. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy // Curr. Opin. Cardiol. - 2008. - N. 23. - P. 296-301.
McLean              A.J., Le Couteur D.G. Aging biology and geriatric clinical pharmacology // Pharmacol. Rev. - 2004. - N. 56. - P. 163-184.
Bowie              M.W., Slattum P.W. Pharmacodynamics in older adults: a review // Am J Geriatr Pharmacother. - 2007. - N. 5. - P. 263-303.
Aronow              W.S., Frishman W.H., Cheng-Lai A. Cardiovascular drug therapy in the elderly // Cardiol.
Rev. - 2007. - N. 15. - P. 195-215.
Qasqas              S.A., McPherson C., Frishman W.H. et al. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation // Cardiol. Rev. - 2004. - N. 12. - P. 240-261.
Levey              A.S., Eckardt K.U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. - 2005. -
N. 67. - P. 2089-2100.
Levey              A.S., Uhlig K. Which antihypertensive agents in chronic kidney disease? // Ann. Intern. Med. -
- N. 144. - P. 213-215.
41 .Jafar T.H., Stark P.C., Schmid C.H. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis // Ann. Intern. Med. - 2003. - N. 139. - P. 244-252.
42.Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. - 2008. - N. 29. - P. 2388-2442.
43.Strippoli G.F., Navaneethan S.D., Johnson D.W. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials // BMJ. - 2008. - N. 336. - P. 645-651.
44.Moher D., Schulz K.F., Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials // Lancet. - 2001. - N. 357. - P. 11911194.
45.Stanley K. Design of randomized controlled trials // Circulation. - 2007. - N. 115. - P. 1164-1169.
Pitt              B., Segal R., Martinez F.A. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) // Lancet. - 1997. - N. 349. - P. 747752.
Pitt              B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II // Lancet. - 2000. - N. 355. - P. 1582-1587.
Meinert              C.L. Clinical trials: the gold standard for evaluation of therapy // Ophthalmology. - 1996. - N. 103. - P. 869-870.
Cohn              J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. - 2001. - N. 345. - P. 1667-1675.
Yusuf              S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators // N. Engl. J. Med. - 2000. - N. 342. - P. 145-153.
51 .Hamm C.W., Bertrand M., Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines // Lancet. - 2001. - N. 358. - P. 1533-1538.
Echt              D.S., Liebson P.R., Mitchell L.B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial // N. Engl. J. Med. - 1991. - N. 324. - P. 781-788.
Comparison              of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators // N. Engl. J. Med. - 1996. - N. 335. - P. 217-225.
Maggioni              A.P., Darne B., Atar D. et al. FDA and CPMP rulings on subgroup analyses // Cardiology. -
- N. 107. - P. 97-102.
Fox              K., Ford I., Steg P.G. et al. Ivabradine for patients with stable coronary artery disease and left- ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial // Lancet. - 2008. - N. 372. - P. 807-816.
Trewby              P.N., Reddy A.V., Trewby C.S. et al. Are preventive drugs preventive enough? A study of patients’ expectation of benefit from preventive drugs // Clin. Med. - 2002. - N. 2. - P. 527-533.
Glasziou              P.P., Irwig L.M. An evidence based approach to individualising treatment // BMJ. - 1995. - N. 311. - P. 1356-1359.
Hypertension              (persistently high blood pressure) in adults. National Institute of Clinical Excellence (NICE). Clinical Guideline No. 34. 2008. http://www.nice.org.uk
Wilt              T.J., Bloomfield H.E., MacDonald R. et al. Effectiveness of statin therapy in adults with coronary heart disease // Arch. Intern. Med. - 2004. - N. 164. - P. 1427-1436.
Antithrombotic              Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. - 2002. - N. 324.- P. 71-86.
61 .Topol E.J. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial // Lancet. - 2001. - N. 357. - P. 1905-1914.
62.Shibata M.C., Flather M.D., Wang D. Systematic review of the impact of beta-blockers on mortality and hospital admissions in heart failure // Eur. J. Heart Fail. - 2001. - N. 3. - P. 351-357.
Pocock              S.J., Travison T.G., Wruck L.M. How to interpret figures in reports of clinical trials // BMJ. -
- N. 336. - P. 1166-1169.
Pitt              B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators // N. Engl. J. Med. - 1999. - N. 341. - P. 709-717.
Baigent              C., Collins R., Appleby P. et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group // BMJ. - 1998. - N. 316. - P. 1337-1343.
Angus              D.C., Laterre P.F., Helterbrand J. et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis // Crit. Care Med. - 2004. - N. 32. - P. 2199-2206.
Flather              M.D., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group // Lancet. - 2000. - N. 355. - P. 1575-1581.
Rothwell              P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?" // Lancet. - 2005. - N. 365. - P. 82-93.
Effectiveness              of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) // Lancet. - 1986. - N. 1. - P. 397-402.
MRC/BHF              Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial // Lancet. - 2002. - N. 360. - P. 7-22.
Effects              of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators // Lancet. - 2000. - N. 355. - P. 253-259.
Yusuf              S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - N. 358. - P. 1547-1559.
73.Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group // Lancet. - 1994. - N. 343. - P. 311-322.
Rothwell              P.M., Eliasziw M., Gutnikov S.A. et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis // Lancet. - 2003. - N. 361. - P. 107
116.
Yusuf              S., Teo K., Woods K. Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention // Circulation. - 1993. - N. 87. - P. 2043-2046.
76.ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group // Lancet. - 1995. - N. 345. - P. 669-685.
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy)
Collaborative Group // Lancet. - 1994. - N. 343. - P. 619-629.
Endoh              M., Hori M. Acute heart failure: inotropic agents and their clinical uses // Expert. Opin. Pharmacother. - 2006. - N. 7. - P. 2179-2202.
Bayram              M., De Luca L., Massie M.B. et al. Reassessment of dobutamine,              dopamine,              and              milrinone in
the management of acute heart failure syndromes // Am. J. Cardiol. - 2005. - N. 96. - 47-58.
Lehtonen              L.A., Antila S., Pentikainen P.J. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents // Clin. Pharmacokinet. - 2004. - N. 43. - P. 187-203.
81 .Kirsten R., Nelson K., Kirsten D. et al. Clinical pharmacokinetics of vasodilators. Part II // Clin. Pharmacokinet. - 1998. - N. 35. - P. 9-36.
82.Schoner W., Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action // Am. J. Cardiovasc. Drugs. - 2007. - N. 7. - P. 173-189.
Ahmed              A., Rich M.W., Love T.E. et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial // Eur. Heart J. - 2006. - N. 27. - P. 178-186.
Adams              K.F. Jr., Patterson J.H., Gattis W.A. et al. Relationship of serum digoxin concentration to
mortality and morbidity in women in the digitalis investigation group              trial: a              retrospective              analysis // J. Am.
Coll. Cardiol. - 2005. - N. 46. - P. 497-504.
Rathore              S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure // JAMA. - 2003. - N. 289. - P. 871-878.
Van              Veldhuisen D.J., de Graeff P.A., Remme W.J. et al. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? // J. Am. Coll. Cardiol. - 1996. - N. 28. - P. 813-819.
Bauman              J.L., Didomenico R.J., Galanter W.L. Mechanisms, manifestations, and management of digoxin toxicity in the modern era // Am. J. Cardiovasc. Drugs. - 2006. - N. 6. - P. 77-86.
Vernon              M.W., Heel R.C., Brogden R.N. Enoximone. A review of its pharmacological properties and therapeutic potential // Drugs. - 1991. - N. 42. - P. 997-1017.
89.Shipley J.B., Tolman D., Hastillo A. et al. Milrinone: basic and clinical pharmacology and acute and chronic management // Am. J. Med. Sci. - 1996. - N. 311. - P. 286-291.
90.Thackray S., Easthaugh J., Freemantle N. et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a metaregression analysis // Eur. J. Heart Fail. - 2002. - N. 4. - P. 515-529.
91 .El Mokhtari N.E., Arlt A., Meissner A. et al. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine // Eur. J. Med. Res. - 2007. - N. 12. - P. 563-567.
Dasta              J.F., Bauman J.L., Danziger L.H. et al. Dobutamine vs dopamine: another look // Pharmacotherapy. - 1990. - N. 10. - P. 417-418.
Pickworth              K.K. Long-term dobutamine therapy for refractory congestive heart failure // Clin Pharm. - 1992. - N. 11. - P. 618-624.
Ruffolo              R.R. Jr. The pharmacology of dobutamine // Am. J. Med. Sci. - 1987. - N. 294. - P. 244-248.
Cavusoglu              Y. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure // Expert. Opin. Pharmacother. - 2007. - N. 8. - P. 665-677.
Antila              S., Sundberg S., Lehtonen L.A. Clinical pharmacology of levosimendan // Clin. Pharmacokinet. -
- N. 46. - P. 535-552.
Rudo              T., Kowey P. Atrial fibrillation: choosing an antiarrhythmic drug // Curr. Cardiol. Rep. - 2006. - N. 8. - P. 370-376.
Wijffels              M.C., Dorland R., Allessie M.A. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d- sotalol // J. Cardiovasc. Electrophysiol. - 1999. - N. 10. - P. 178-193.
Esato              M., Shimizu A., Chun Y.H. et al. Electrophysiologic effects of a class I antiarrhythmic agent, cibenzoline, on the refractoriness and conduction of the human atrium in vivo // J. Cardiovasc.
Pharmacol. - 1996. - N. 28. - P. 321-327.
Bru              P., Cointe R., Paganelli F. et al. Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias // Cardiovasc. Drugs Ther. - 1995. - N. 9. - P. 85-88.
101.Ishibashi K., Inoue D., Sakai R. et al. Effects of disopyramide on the atrial fibrillation threshold in the human atrium // Int. J. Cardiol. - 1995. - N. 52. - P. 177-184.
Tenneze              L., Tarral E., Ducloux N. et al. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism // Clin. Pharmacol. Ther. - 2002. - N. 72. - P. 112-122.
Morike              K., Kivisto K.T., Schaeffeler E. et al. Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial // Clin. Pharmacol. Ther. -
- N. 84. - P. 104-110.
Kirpizidis              C., Stavrati A., Geleris P. et al. Safety and effectiveness of oral quinidine in cardioversion of persistent atrial fibrillation // J. Cardiol. - 2001. - N. 38. - P. 351-354.
Ahmed              S., Rienstra M., Crijns H.J. et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial // JAMA. - 2008. - N. 300. - P. 17841792.
Nattel              S., Talajic M. Recent advances in understanding the pharmacology of amiodarone // Drugs. - 1988. - N. 36. - P. 121-131.
Freedman              M.D., Somberg J.C. Pharmacology and pharmacokinetics of amiodarone // J. Clin. Pharmacol. - 1991. - N. 31. - P. 1061-1069.
Chow              M.S. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use // Ann. Pharmacother. - 1996. - N. 30. - P. 637-643.
109.Singh B.N., Connolly S.J., Crijns H.J. et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter // N. Engl. J. Med. - 2007. - N. 357. - P. 987-999.
Dronedarone:              drondarone, SR 33589, SR 33589B // Drugs. - 2007. - N. 8. - P. 171-175.
Foster              R.H., Wilde M.I., Markham A. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation // Drugs. - 1997. - N. 54. - P. 312-330.
Kafkas              N.V., Patsilinakos S.P., Mertzanos G.A. et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter //
Int. J. Cardiol. - 2007. - N. 118. - P. 321-325.
Brown              B.G., Zhao X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk // Am. J. Cardiol. - 2008. - N. 101. - P. 58-62.
Weiner              M. Clinical pharmacology and pharmacokinetics of nicotinic acid // Drug Metab. Rev. - 1997. - N. 9. - P. 99-106.
Filippatos              T., Milionis H.J. Treatment of hyperlipidaemia with fenofibrate and related fibrates // Expert. Opin. Investig. Drugs. - 2008. - N. 17. - P. 1599-1614.
May              H.T., Anderson J.L., Pearson R.R. et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study) // Am. J.
Cardiol. - 2008. - N. 101. - P. 486-489.
Curtin              P.O., Jones W.N. Therapeutic rationale of combining therapy with gemfibrozil and simvastatin // J. Am. Pharm. Assoc. - 2007. - N. 47. - P. 140-146.
Reyderman              L., Kosoglou T., Statkevich P. et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil // Int. J. Clin. Pharmacol. Ther. - 2004. - N. 42. - P. 512-518.
Kosoglou              T., Statkevich P., Johnson-Levonas A.O. et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions // Clin. Pharmacokinet. - 2005. - N. 44. - P. 467-494.
Gottlieb              I., Agarwal S., Gautam S. et al. Aortic plaque regression as determined by magnetic resonance imaging with high-dose and low-dose statin therapy // J. Cardiovasc. Med. - 2008. - N. 9. - P. 700-706.
Ballantyne              C.M., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial // J. Am. Coll. Cardiol. - 2008. - N. 52. - P. 626-632.
Wang              C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results // Trends Mol. Med. - 2008. - N. 14. - P. 37-44.
Kobayashi              M., Chisaki I., Narumi K. et al. Association between risk of myopathy and cholesterol- lowering effect: a comparison of all statins // Life Sci. - 2008. - N. 82. - P. 969-975.
124.Sathasivam S., Lecky B., Manohar R. et al. Neuralgic amyotrophy // Bone Joint Surg. Br. - 2008. - N. 90. - P. 550-553.
Frishman              W.H., Horn J. Statin-drug interactions: not a class effect // Cardiol. Rev. - 2008. - N. 16. - P. 205-212.
Zannad              F. Aldosterone antagonist therapy in resistant hypertension // J. Hypertens. - 2007. - N. 25. - P. 747-750.
Teiwes              J., Toto R.D. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride // Am. J. Hypertens. - 2007. - N. 20. - P. 109-117.
Cleland              J.G., Coletta A., Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure // Am. J. Med. - 2006. - N. 119. - P. 26-36.
Wang              D.J., Gottlieb S.S. Diuretics: still the mainstay of treatment // Crit.              Care              Med.              -              2008. - N. 36. -
P. 89-94.
Kaplan              N.M. The place of diuretics in preventing cardiovascular events // J. Hum. Hypertens. - 2004. - N. 18. - Vol. 2. - P. 29-32.
Psaty              B.M., Lumley T., Furberg C.D. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies // JAMA. - 2004. - N. 292. - P. 43-44.
132.Salvetti A., Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update // J. Am. Soc. Nephrol. - 2006. - N. 17. - P. 25-29.
Konstam              M.A., Gheorghiade M., Burnett J.C. Jr. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial // JAMA. - 2007. - N. 297. - P. 1319-1331.
Gheorghiade              M., Konstam M.A., Burnett J.C. Jr. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials // JAMA. - 2007. - N. 297. - P. 1332-1343.
Heran              B.S., Wong M.M., Heran I.K. et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension // Cochrane Database Syst. Rev. - 2008. CD003823.
Matchar              D.B., McCrory D.C., Orlando L.A. et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension // Ann. Intern. Med. - 2008. - N. 148. - P. 16-29.
McMurray              J.J., Pfeffer M.A., Swedberg K. et al. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? // Circulation. - 2004. - N. 110. - P. 3281-3288.
Dagenais              G.R., Pogue J., Fox K. et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials // Lancet. - 2006. - N. 368. - P. 581-588.
Danchin              N., Cucherat M., Thuillez C. et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials // Arch. Intern. Med. - 2006. - N. 166. - P. 787-796.
Randomised              trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack // Lancet. - N. 358. - P. 1033-1041.
141.Strippoli G.F., Bonifati C., Craig M. et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease // Cochrane Database Syst. Rev. - 2006. CD006257.
142.Lakhdar R., Al-Mallah M.H., Lanfear D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials // J. Card. Fail. - 2008. - N. 14. - P. 181-188.
143.Staessen J.A., Li Y., Richart T. Oral renin inhibitors // Lancet. - 2006. - N. 368. - P. 1449-1456.
Parving              H.H., Persson F., Lewis J.B. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2008. - N. 358. - P. 2433-2446.
Musini              V.M., Fortin P.M., Bassett K. et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension // Cochrane Database Syst. Rev. - 2008. CD007066.
Pitt              B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction // N. Engl. J. Med. - 2003. - N. 348. - P. 1309-1321.
Pitt              B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study // Circulation. - 2003. - N. 108. - P. 1831-1838.
Zannad              F., Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure // Heart Fail Rev. - 2005. - N. 10. - P. 71-78.
Pitt              B. The role of aldosterone blockade in patients with heart failure // Heart Fail Rev. - 2005. - N. 10. - P. 79-83.
Reiter              M.J. Cardiovascular drug class specificity: beta-blockers // Prog. Cardiovasc. Dis. - 2004. - N. 47.- P. 11-33.
Haeusler              G. Pharmacology of beta-blockers: classical aspects and recent developments // J. Cardiovasc. Pharmacol. - 1990. - N. 16. - Vol. 5. - P. 1-9.
Kendall              M.J. Pharmacology of third-generation beta-blockers: greater benefits, fewer risks // J. Cardiovasc. Pharmacol. - 1989. - N. 14. - Vol. 7. - P. 4-8.
Escobar              C., Barrios V. Calcium channel blocker-based combination therapy. The best approach in the treatment of high-risk hypertension? // Int. J. Clin. Pract. - 2008. - N. 62. - P. 670-672.
Epstein              B.J., Vogel K., Palmer B.F. Dihydropyridine calcium channel antagonists in the management of hypertension // Drugs. - 2007. - N. 67. - P. 1309-1327.
Grossman              E., Messerli F.H. Calcium antagonists // Prog. Cardiovasc. Dis. - 2004. - N. 47. - P. 34-57.
McInnes              G.T. Clinical pharmacology of verapamil // Br. J. Clin. Pract. Suppl. - 1988. - N. 60. - P. 3-8.
Henry              P.D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem // Am. J. Cardiol. - 1980. - N. 46. - P. 1047-1058.
Del              Colle S., Morello F., Rabbia F. et al. Antihypertensive drugs and the sympathetic nervous system // J. Cardiovasc. Pharmacol. - 2007. - N. 50. - P. 487-496.
Mayer              B., Beretta M. The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles // Br. J. Pharmacol. - 2008. - N. 155. - P. 170-184.
Zimmermann              N., Hohlfeld T. Clinical implications of aspirin resistance // Thromb. Haemost. - 2008. - N. 100. - P. 379-390.
De              Luca G., Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST- segment elevation myocardial infarction // Thromb. Haemost. - 2008. - N. 100. - P. 184-195.
Bauer              K.A. New anticoagulants // Curr. Opin. Hematol. - 2008. - N. 15. - P. 509-515.
163.Stehle S., Kirchheiner J., Lazar A. et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization // Clin. Pharmacokinet. - 2008. - N. 47. - P. 565-594.
Kashani              A., Giugliano R.P. Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization // Am. J. Cardiovasc. Drugs. - 2008. - N. 8. - P. 187-197.
Borer              J.S., Heuzey J.Y. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor // Am. J. Ther. - 2008. - N. 15. - P. 461-473.